ACE2 and COVID-19: Compelling evidence to support this hypothesis comes from a recent article, which reports that circulating ACE2 activity in COVID-19 patients (at a median of 35-day post-infection) was 97-fold higher (p < 0.0001, and in accordance to disease severity) than control subjects, and it remained persistently elevated at 4-month post-infection [33].